O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells

Cancer Research

Volumn 73, Issue 16, 2013, Pages 5277-5287

  Itkonen, Harri M ^a   Minner, Sarah ^e   Guldvik, Ingrid J ^a   Sandmann, Mareike Julia ^e   Tsourlakis, Maria Christina ^e   Berge, Viktor ^c   Svindland, Aud ^d   Schlomm, Thorsten ^e   Mills, Ian G ^a,b,c  

^a UNIVERSITY OF OSLO   (Norway)

^b Departments of Cancer Prevention   (Norway)

^c Urological Department   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 ADAMANTYLETHYL) 2 [(4 CHLOROPHENYL)AZAMETHYLENE] 4 OXO 1,3 THIAZAPERHYDROINE 6 CARBOXYLIC ACID; GLYCOSYLTRANSFERASE INHIBITOR; HEXOSAMINE; MESSENGER RNA; MYC PROTEIN; N ACETYLGLUCOSAMINYLTRANSFERASE; SMALL INTERFERING RNA; ST 045849; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RECURRENCE; CANCER STAGING; CARBOHYDRATE METABOLISM; CELL CYCLE PROGRESSION; CELL VIABILITY; CONTROLLED STUDY; DNA REPLICATION; DRUG TARGETING; ENZYME INHIBITION; GENE OVEREXPRESSION; GENE SILENCING; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RNA INTERFERENCE; UPREGULATION;

EID: 84882607514     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0549     Document Type: Article

References (48)

1. Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schroder FH, Sternberg CN, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012;61:11-25.
2. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 2011;30:2719-33.
3. Moon JS, Jin WJ, Kwak JH, Kim HJ, Yun MJ, Kim JW, et al. Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose- 2,6-bisphosphatase 2 in prostate cancer cells. Biochem J 2011;433: 225-33.
4. Wellen KE, Thompson CB. A two-way street: reciprocal regulation of metabolism and signalling. Nat Rev Mol Cell Biol 2012;13:270-6.
5. Wellen KE, Lu C, Mancuso A, Lemons JM, Ryczko M, Dennis JW, et al. The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev 2010;24: 2784-99.
6. Hanover JA, Krause MW, Love DC. Bittersweet memories: linking metabolism to epigenetics through O-GlcNAcylation. Nat Rev Mol Cell Biol 2012;13:312-21.
7. Butkinaree C, Park K, Hart GW. O-linked beta-N-acetylglucosamine (O-GlcNAc): extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. Biochim Biophys Acta 2010;1800:96-106.
8. Capotosti F, Guernier S, Lammers F, Waridel P, Cai Y, Jin J, et al. OGlcNAc transferase catalyzes site-specific proteolysis of HCF-1. Cell 2011;144:376-88.
9. Hanover JA, Krause MW, Love DC. Bittersweet memories: linking metabolism to epigenetics through O-GlcNAcylation. Nat Rev Mol Cell Biol 2012;13:312-21.
10. Chatham JC, Marchase RB. Protein O-GlcNAcylation: a critical regulator of the cellular response to stress. Curr Signal Transduct Ther 2010;5:49-59.
11. Caldwell SA, Jackson SR, Shahriari KS, Lynch TP, Sethi G, Walker S, et al. Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene 2010;29:2831-42.
12. Mi W, Gu Y, Han C, Liu H, Fan Q, Zhang X, et al. O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy. Biochim Biophys Acta 2011;1812:514-9.
13. Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K, Reginato MJ. Critical role of O-GlcNAc transferase in prostate cancer invasion, angiogenesis and metastasis. J Biol Chem 2012;287:11070-81.
14. SchlommT, Iwers L, Kirstein P, Jessen B, Kollermann J, Minner S, et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 2008;21:1371-8.
15. Erbersdobler A, Fritz H, Schnoger S, Graefen M, Hammerer P, Huland H, et al. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. Eur Urol 2002;41:40-6.
16. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999;59:803-6.
17. Minner S, Jessen B, Stiedenroth L, Burandt E, Kollermann J, Mirlacher M, et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 2010;16:1553-60.
18. Gross BJ, Kraybill BC, Walker S. Discovery of O-GlcNAc transferase inhibitors. J Am Chem Soc 2005;127:14588-9.
19. Lima VV, Giachini FR, Carneiro FS, Carvalho MH, Fortes ZB, Webb RC, et al. O-GlcNAcylation contributes to the vascular effects of ET-1 via activation of the RhoA/Rho-kinase pathway. Cardiovasc Res 2011;89: 614-22.
20. Gorlov IP, Byun J, Gorlova OY, Aparicio AM, Efstathiou E, Logothetis CJ. Candidate pathways and genes for prostate cancer: a metaanalysis of gene expression data. BMC Med Genomics 2009;2:48.
21. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010;17:443-54.
22. Van den Steen P, Rudd PM, Dwek RA, Opdenakker G. Concepts and principles of O-linked glycosylation. Crit Rev Biochem Mol Biol 1998; 33:151-208.
23. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, et al. The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980;37:115-32.
24. Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, et al. VCaP, a cell-based model system of human prostate cancer. In vivo 2001;15:163-8.
25. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus Carcinogenesis 1997;18:1215-23.
26. Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K, Reginato MJ. Critical role of O-Linked beta-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem 2012;287:11070-81.
27. Ranuncolo SM, Ghosh S, Hanover JA, Hart GW, Lewis BA. Evidence of the involvement of O-GlcNAc-modified humanRNApolymerase IICTD in transcription in vitro and in vivo. J Biol Chem 2012;287:23549-61.
28. Hammerer P, Madersbacher S. Landmarks in hormonal therapy for prostate cancer. BJU Int 2012;110 Suppl 1:23-9.
29. Kazemi Z, Chang H, Haserodt S,McKen C, Zachara NE. O-linked beta- N-acetylglucosamine (O-GlcNAc) regulates stress-induced heat shock protein expression in a GSK-3beta-dependent manner. J Biol Chem 2010;285:39096-107.
30. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
31. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009;37:1-13.
32. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
33. Chou TY, Hart GW, Dang CV. c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J Biol Chem 1995;270:18961-5.
34. Chou TY, Dang CV, Hart GW. Glycosylation of the c-Myc transactivation domain. Proc Natl Acad Sci U S A 1995;92:4417-21.
35. El Gammal AT, Bruchmann M, Zustin J, Isbarn H, Hellwinkel OJ, Kollermann J, et al. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res 2010;16:56-64.
36. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher- Sananikone E, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012;149: 656-70.
37. Krzeslak A, Forma E, Bernaciak M, Romanowicz H, Brys M. Gene expression of O-GlcNAc cycling enzymes in human breast cancers. Clin Exp Med 2012;12:61-5.
38. Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, et al. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis 2010;13:311-5.
39. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 2008;21:1156-67.
40. Sato H, Minei S, Hachiya T, Yoshida T, Takimoto Y. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients. Int J Urol 2006;13:761-6.
41. Fleming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Johnston B, et al. Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res 1986;46:1535-8.
42. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
43. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature 2010;468: 1067-73.
44. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011;108: 16669-74.
45. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011;478:524-8.
46. Westermarck J, HahnWC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008;14: 152-60.
47. Cheng J, Wang D, Wang Z, Yeh ET. SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase Mol Cell Biol 2004;24:6021-8.
48. Ngoh GA, Hamid T, Prabhu SD, Jones SP. O-GlcNAc signaling attenuates ER stress-induced cardiomyocyte death. Am J Physiol Heart Circ Physiol 2009;297:H1711-9.